BlackJack3D Yet another cheap Big Pharma stock Having recently written about the cratered pharma stock and value opportunity in Pfizer (PFE), charting the big pharma sell-offs, reveals a nearly as strong downtrend in Bristol-Myers Squibb (NYSE:BMY). The company is in a similar phase of R&D cycling and acquisitions to fill its next cycle of drugs for the next decade. Bristol Myers does not have the stigma around it from being a vaccine producer during COVID-19, but they also have their issues to reckon w ...